Washington Trust’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Washington Trust’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-167	Closed	-$500	–	839
2023 Q3	$500	Hold	167	–	–	﹤0.01%	878
2023 Q2	$5.15K	Hold	167	–	–	﹤0.01%	703
2023 Q1	$8.25K	Hold	167	–	–	﹤0.01%	677
2022 Q4	$4.1K	Hold	167	–	–	﹤0.01%	744
2022 Q3	$11K	Hold	167	–	–	﹤0.01%	632
2022 Q2	$7K	Hold	167	–	–	﹤0.01%	683
2022 Q1	$8K	Hold	167	–	–	﹤0.01%	690
2021 Q4	$10K	Hold	167	–	–	﹤0.01%	665
2021 Q3	$8K	Hold	167	–	–	﹤0.01%	797
2021 Q2	$10K	Hold	167	–	–	﹤0.01%	778
2021 Q1	$10K	Hold	167	–	–	﹤0.01%	755
2020 Q4	$11K	Hold	167	–	–	﹤0.01%	739
2020 Q3	$42K	Hold	167	–	–	﹤0.01%	474
2020 Q2	$28K	Hold	167	–	–	﹤0.01%	493
2020 Q1	$12K	Buy	+167	New	+$13K	﹤0.01%	638
2018 Q3	–	Sell	-167	Closed	-$10K	–	283
2018 Q2	$10K	Buy	+167	New	+$9.82K	﹤0.01%	670

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LWM

Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return

WCG

Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Washington Trust's BCLI Position: Q4 2023 in Review

Washington Trust sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2023, closing a stake of 167 shares — an estimated $500 sold.

Washington Trust first reported a position in BCLI in Q2 2018 and held it in 16 quarters. The position peaked at $42K in Q3 2020. 46 funds tracked by Wall St. Rank hold BCLI as of Q4 2023.

Washington Trust reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2023 after selling out during the quarter.
Washington Trust sold 167 BRAINSTORM CELL THERAPUTC shares in Q4 2023, an estimated $500.
Washington Trust first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2018 and held it in 16 quarters.
Washington Trust's BRAINSTORM CELL THERAPUTC position peaked at $42K in Q3 2020.
46 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2023.

Based on Washington Trust's 13F filing for Q4 2023, filed 18 Jan 2024.